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1.1. Endocrine/systemic renin–angiotensin systems
The renin–angiotensin system (RAS) is one of the most important
systems in blood pressure (BP) regulation. The RAS has been the target
of active research interest since the discovery of renin more than
100 years ago (Tigerstedt, 1898), reﬂecting its importance in the
pathogenesis of hypertension and other cardiovascular diseases (Re,
2004; Hsueh & Wyne, 2011; Vijayaraghavan & Deedwania, 2011; Ellis
et al., 2012; Te Riet et al., 2015). In the traditional view of the systemic
RAS, active renin is generated by the removal of a prosegment from
prorenin, a precursor of renin, in the juxtaglomerular cells of the kidney.
Active renin is released into the circulation and cleaves its only known
substrate, angiotensinogen (AGT), which is primarily synthesized inense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ther converted into Ang II by angiotensin-converting enzyme (ACE),
which is predominantly expressed on endothelial cells of the pulmo-
nary circulation and the kidney (Cushman & Cheung, 1971; Ryan
et al., 1976). Ang II, the major bioactive peptide of the RAS, binds to G-
protein-coupled Ang II receptors, including AT1R and AT2R
(Vinturache & Smith, 2014), and contributes to BP regulation as well
as the pathogenesis of hypertension by regulating sympathetic activity,
vasoconstriction, sodium retention, thirst, and aldosterone synthesis
and secretion from the adrenal cortex.
1.2. Tissue/local renin–angiotensin systems
There is considerable evidence that a majority of RAS components
are also present in many tissues and exert indispensable roles in BP
regulation (Bader, 2010). Renin production is the rate-limiting step for
systemic RAS activity. However, the kidney secretes both renin and
prorenin in response to a decrease in renal perfusion and sodium chlo-
ride concentration (Hsueh & Baxter, 1991). Although renin is produced
only in the renal juxtaglomerular apparatus, prorenin is synthesized in
many tissues apart from the kidney, including the adrenal gland,
ovary, testis, placenta, retina, and the brain (Danser et al., 1989; Hsueh
& Baxter, 1991; von Lutterotti et al., 1994; Bader et al., 2001). Renin is
produced from prorenin by cleavage of a 43-amino-acid N-terminal
prosegment. This can be accomplished by enzymes such as glandular
kallikrein 13, cathepsin D, and pepsin in vitro (Morris, 1978; Kim
et al., 1991). However, more recent studies in cultured HEK-293 cells
suggest that renin production might not require a speciﬁc enzyme, but
rather is mediated by general hydrolysis in lysosome-like granules of
juxtaglomerular cells (Schmid et al., 2013; Xa et al., 2014). The
prosegment prevents the exposed renin catalytic site from interacting
with AGT, as reﬂected in the fact that prorenin has only 3% of the intrin-
sic activity of fully active renin (Lenz et al., 1991). These ﬁndings have
suggested the concept that prorenin is an inactive biosynthetic precur-
sor of renin (Hsueh & Baxter, 1991). However, this concept cannot ex-
plain why some tissues that only produce prorenin, such as the brain,
have a signiﬁcant amount of Ang II (Hirose et al., 1981; Hermann
et al., 1984). In fact, more recent evidence has shown that prorenin
can be activated independently of conventional enzymes or lysosome-
like granules through association with a membrane protein termed
the (pro)renin receptor (PRR), also called APT6AP2 (Nguyen et al.,
2002).
The PRR is a 350-amino-acid protein composed of a large extracellu-
lar domain (ECD; ~310 amino acids), a single transmembrane domain
(TMD; ~20 amino acids), and an intracellular domain (ICD; ~19 amino
acids). Under physiological conditions, the PRR is expressed at high
levels in the heart, brain and placenta, and at low level in the kidney
and liver (Nguyen et al., 2002). It exists as a homodimer, formed
through interactions involving its ECD and ICD domains (Zhang et al.,
2011; Suzuki-Nakagawa et al., 2014). The discovery of the PRR revealed
a new RAS regulatory mechanism.
The discovery of the PRR revealed a new RAS regulatorymechanism.
The PRR binds and increases the enzymatic activity of renin and
prorenin (Nguyen et al., 2002), functioning as a tissue-originating
activator of prorenin that increases the activity of prorenin to a level com-
parable to that of free, active renin (Nguyen et al., 2002). The association
of proreninwith the PRR ismediated by both the prosegment andmature
fragment of renin (Nabi & Suzuki, 2009; Nabi et al., 2009a). These
interacting regions form the basis for the development of peptides, in-
cluding the handle region peptide (R10P IFLKR15P), the decoy peptide (R-
10PIFLKRMPSI19P), the hinge region peptide (S149PQGVLKEDVF158P) and
the PRO20 peptide (L1PPTRTATFERIPLKKMPSVR20P), which abrogate
PRR–prorenin interactions by competitively binding to the PRR (Nabi &
Suzuki, 2009; Nabi et al., 2009a; Li et al., 2015). The involvement of the
prosegment in PRR binding not only increases the binding afﬁnity, but
also enables prorenin to adopt a conformation suitable for recognitionof the substrate AGT (Nabi et al., 2009b;Morales et al., 2012). The confor-
mational change in prorenin upon PRR binding increases the activity of
prorenin to a level 3- to 4-fold higher than that of renin (Nabi et al.,
2009b), suggesting that prorenin exerts its function mainly at the level
of tissueswhere the PRR is expressed. However, this leaves an interesting
evolutionary question: howdid juxtaglomerular cells of the kidney retain
the ability to cleave prorenin to renin, while most other tissues in the
body use prorenin and probably the PRR as the regulator of the RAS?
Unlike renin, which is secreted by juxtaglomerular cells but func-
tions systematically, the PRR appears to be a bona ﬁde local player,
which serves at the level of the tissue where it is produced. In the kid-
ney, the PRR is mainly expressed in cells of the collecting ducts and in
the distal nephron (Advani et al., 2009), where it may complex with
vacuolar H+-ATPase to regulate proton transport (Advani et al., 2009;
Daryadel et al., 2016). Expression of the PRR is regulated by changes
in sodium concentration induced by the cGMP-dependent protein
kinase (PKG) pathway in the kidney (Huang & Siragy, 2011; Rong
et al., 2015; Quadri & Siragy, 2016). In addition, PRR expression levels
are regulated by Ang II through CREB (cAMP response element binding
protein) in the central nervous system (CNS) during hypertension
(Li et al., 2015), and a cyclooxygenase (COX)-2-dependent pathway in
the kidney (Wang et al., 2014). Increased PRR expression may further
promote the production of Ang II, ultimately resulting in positive feed-
back regulation of the receptor itself and the development of hyperten-
sion (Wang et al., 2014; Yang, 2015).
The PRR is involved in the development of diabetic nephropathy
through enhancement of renal production of the inﬂammatory factors
tumor necrosis factor (TNF)-α and interleukin (IL)-1β (Matavelli et al.,
2010). In addition, the PRR is also an important regulator in smooth
muscle cells, including arterial smooth muscle. A transgenic mouse in
which the PRR is overexpressed in smooth muscle cells is prone to the
development of hypertension in association with increased heart rate
(Burckle et al., 2006). In vitro assays have shown that expression of
the PRR in smoothmuscle cells contributes to cell migration by regulat-
ing cytoskeletal reorganization, small GTPase activation, and pp125FAK
cleavage (Greco et al., 2012). These ﬁndings suggest that expression of
the PRR in smooth muscle may contribute to arterial integrity
(Kurauchi-Mito et al., 2014). Notably, knockout of the PRR in smooth
muscle cells in mice results in nonatherogenic sclerosis in the abdomi-
nal aorta, but leaves BP unaffected (Kurauchi-Mito et al., 2014). This
suggests that the PRR serves other essential functions unrelated to the
RAS that mask its role in hypertension. Actually, the PRR has been iden-
tiﬁed as an essential regulator of Xenopus development through its role
in the Wnt signaling pathway. Here, the PRR mediates activation of the
Wnt receptor, LRP6, by recruiting V-ATPase, resulting in β-catenin acti-
vation (Cruciat et al., 2010). Following up on this, Li and Siragy provided
evidence showing that the PRR may also contribute to high-glucose–
induced podocyte injury through the PRR–Wnt–β-catenin–snail signal-
ing pathway (Li & Siragy, 2014).
Upon binding to prorenin, the PRR engages intracellular signaling
networks independent of Ang II. These include the mitogen-activated
protein kinases (MAPKs), p38 and ERK1/2 (extracellular signal-
regulated kinases 1 and 2, p40/42), and their downstream targets,
such as heat shock protein 27, tumor growth factor (TGF)-β, c-Jun N-
terminal kinase (JNK) and NADPH oxidase, resulting in enhanced pro-
duction of pro-inﬂammatory cytokines and expression of promyelocytic
zinc ﬁnger (PLZF) protein (Feng, 2015). In cultured rat inner medullary
cells, binding of prorenin to the PRR can promote ERK1/2 activation and
COX-2 upregulation in an Ang II-independent manner (Gonzalez et al.,
2012). Over-activation of the PRR contributes to diabetic nephropathy,
as evidenced by the fact that PRR blockade abolishes MAPK activation
and reverses the progression of nephropathy (Ichihara et al., 2004,
2006; Takahashi et al., 2007). Consistent with this, treatment with
high levels of glucose increases PRR levels via protein kinase C (PKC)–
Raf–ERK and PKC–JNK–c-Jun. signaling pathways (Huang & Siragy,
2010). This renal-protective effect of PRR blockade also involves the
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that over-activation of the PRR contributes to diabetic nephropathy
through RAS-independent signaling pathways. In addition, renin in-
duces tyrosine or serine phosphorylation of the PRR in vitro indepen-
dent of Ang II (Nguyen et al., 2002). Whether these phosphorylation
events directly link the PRR to activation of MAPK or other Ang
II-independent signal transduction pathways is currently unknown.
2. The (pro) renin receptor is a master regulator
of blood pressure in the brain renin–angiotensin system
The existence of a blood–brain barrier (BBB) between the brain and
the circulation prevents circulating RAS components, including renin
and Ang II, from reaching most brain area, except for the
circumventricular organs (CVOs), such as the subfornical organ (SFO),
the vascular organ of lamina terminalis (OVLT) and area posterma
(AP), under physiological conditions (Bader, 2010). It is now well
accepted that the brain has its own local RAS, in part because themajor-
ity of RAS components are known to be expressed in the brain. Both
AT1R and AT2R are abundantly expressed in the CNS (Bunnemann
et al., 1992; Johren et al., 1995; Lenkei et al., 1996; Zhuo et al., 1998;
Allen et al., 2000). AT1R is expressed in brain areas involved in BP and
ﬂuid homeostasis, including the paraventricular nucleus (PVN) and
the supraoptic nucleus of the hypothalamus, the rostral ventral lateral
medulla (RVLM), the nucleus tractus of solitarii (NTS), the SFO, and
the AP. The presence of AT1R in the SFO is indispensable for Ang
II-induced hypertension (Sakai et al., 2007). AT2R is expressed at a rela-
tively lower level in the lateral septum, several thalamic nuclei, the sub-
thalamic nucleus, the locus coeruleus, and the inferior olive nucleus
(Zhuo et al., 1998). AT2R exerts an antagonistic effect on AT1R upon
binding to their common ligand, Ang II, and thus appears to function
as a negative regulator of BP (Li et al., 2003). The opposite function of
these two receptors suggests the existence of a ﬁne regulatory network,
but the exact mechanisms underlying its operation are not yet clear.
ACE is also prominently expressed throughout the brain (Zhuo et al.,
1998), enabling Ang II to be produced locally. Transgenic mice with in-
creased Ang II generation in the brain develop hypertension (Morimoto
et al., 2001, 2002), highlighting the physiological relevance of this local
Ang II production. ACE2 (Tipnis et al., 2000), a mono-carboxypeptidase
sharing 42% homology with ACE, further cleaves Ang II to Ang-(1–7).
Ang-(1–7) has an effect opposite that of Ang II in that it stimulates nitric
oxide (NO) release, improves baroreceptor reﬂexes sensitivity, and pro-
motes vasodilation (Rabelo et al., 2011). Consistent with this, overex-
pression of human ACE2 in neurons or speciﬁcally in the RVLM or SFO
causes a reduction in BP in Ang II-induced hypertensive mice and spon-
taneously hypertensive rats (SHR) (Yamazato et al., 2007; Feng et al.,
2008; Xia et al., 2015). AGT in the brain is synthesized and secreted
from astroglial cells (Sernia & Mowchanuk, 1983; Campbell et al.,
1984; Deschepper et al., 1986) and neurons (Yang et al., 1999), and its
levels are high in cerebrospinal ﬂuid (Schelling et al., 1980). In contrast,
whether renin and prorenin in the brain are sufﬁcient to convert AGT
into bioactive angiotensin peptides has remained controversial for de-
cades owing to the undetectable levels of active renin in the CNS
(Cuadra et al., 2010). Although enzymes such as tonin and cathepsins
are abundant in the CNS (Klickstein et al., 1982; Lomez et al., 2002),
there is no solid evidence to show that the enzymatic pathway for
Ang II generation by tonin functions under physiological conditions.
Our recent studies showed that the PRR is a master regulator of cen-
tral BP that contributes to the majority of Ang II generation in the brain
(Li et al., 2012b, 2014). In the CNS, PRRmRNAand protein are expressed
mainly in neurons and to a lesser extent in astrocytes. In cardiovascular
regulatory nuclei of the brain, including the SFO, PVN, RVLM, NTS and
AP, the PRR is expressed exclusively in neurons, and not astrocytes, as
shown in Fig. 1. However, in the lateral cortex of the brain, some PRR
immunostaining is detectable in astrocytes (Shan et al., 2008; Li et al.,
2012a, 2012b). There is also evidence for expression of PRR protein inmicroglial cells, and it has been shown that prorenin promotes the re-
lease of pro-inﬂammatory factors in cultured microglial cells through
activation of the NF-κB signaling pathway (Shi et al., 2014). However,
the functional importance of the PRR in microglial cells has not yet
been clearly established.
Evidence for the importance of the PRR in the central regulation of
BP comes from studies of PRR knockdown in the mouse brain (Li et al.,
2012a). Knockdown of the PRR in the SFO of the human renin and
AGT transgenic hypertensive mouse model by intracerebroventricular
(ICV) delivery of short-hairpin RNA was shown to signiﬁcantly reduce
PRR expression level, leading to decreased BP and cardiac and vasomo-
tor sympathetic tone, and improved baroreceptor reﬂex sensitivity (Li
et al., 2012a). These changes were associated with a concomitant de-
crease in AT1R expression and vasopressin levels in the SFO and PVN, re-
spectively (Li et al., 2012a). In a study by Raizada and colleagues (Shan
et al., 2010), knockdown of the PRR in the supraoptic nucleus of SHR
model animals was found to reduce BP and cause a decrease in heart
rate and plasma vasopressin. To further test the hypothesis that PRR-
mediated, non-proteolytic activation of prorenin is the main source of
Ang II in the brain, we generated a neuron-speciﬁc PRR (ATP6AP2)-
knockout mouse model using the Cre–LoxP system. Importantly, PRR
knockout in neurons signiﬁcantly decreased the elevated BP and Ang
II formation induced by ICV infusion of prorenin (Li et al., 2014). Fur-
thermore, PRR knockout in neurons prevented the development of
deoxycorticosterone acetate (DOCA)-salt-induced hypertension as
well as activation of cardiac and vasomotor sympathetic tone (Li et al.,
2014). In summary,most RAS components are found in the CNS. Instead
of active renin, prorenin, activated by binding to PRR, might be the key
angiotensinogenase in the CNS. Aswe previously reported, the neuronal
PRR is present in the cell membrane as well as the cytoplasm (Li et al.,
2014). Accordingly, we propose that the PRR acts through two path-
ways of Ang II formation – intracellular and extracellular – to serve as
amaster regulator of the brain RAS and sympathetic activity in neurons,
as shown in Fig. 2.
3. The development of (pro)renin receptor antagonists
Despite the commercial availability of dozens of antihypertensive
drugs, efforts to control BP in hypertensive patients still faces many
challenges. In approximately 20–30% of hypertensive patients, BP is
not controlled by existing drugs (Calhoun et al., 2008), and
hypertension-related cardiovascular diseases are still the number one
cause of morbidity and mortality in the USA (Kochanek et al., 2015). A
major category of antihypertensive drugs encompasses those that tar-
get the RAS, including ACE-inhibitors, AT1R blockers, and renin inhibi-
tors (Fig. 3). These drugs function at different steps in the RAS
cascade, providing important treatment options for patients (Feig
et al., 2010). However, long-term administration of ACE-inhibitors or
AT1R blockers causes elevation of circulating active renin levels and en-
hanced production of Ang I and Ang II, with subsequent return of aldo-
sterone secretion to pre-treatment levels (Pitt, 1995; Riccioni, 2013).
The development of renin antagonists has been a priority for more
than 50 years since the initial discovery that renin production is the
rate-limiting step in the RAS signaling cascade. Importantly, the
discovery of aliskiren, the ﬁrst non-peptide, oral renin inhibitor with
long-term effectiveness, has improved treatment efﬁcacy by reducing
the activity of rebound elevation of renin and Ang II levels (van den
Meiracker & Jan Danser, 2007). Aliskiren exerts its effects by blocking
the association of renin with its substrate angiotensinogen, but not
with the PRR. Alisikiren also decreases PRR protein levels in glomeruli,
tubules and cortical vessels, exerting an additional renal-protective
role in hypertension (Feldman et al., 2008). Nevertheless, aliskiren
does increase renin levels (Feldman et al., 2008), suggesting activation
of a feedback network to the RAS. Consistentwith theseﬁndings, clinical
data show that aliskiren works better when combined with other anti-
hypertensive drugs (Azizi et al., 2004; O'Brien et al., 2007; Siragy, 2011).
Fig. 1. Expression of the PRR in brain regions involved in BP regulation. (A) A schematic showing the key cardiovascular regulatory brain nuclei. (B) Brain tissues from C57Bl/6J mice were
stainedwith antibodies against themouse PRR (red), the neuronalmarkerNeuN (blue), and the astrocytemarker GFAP (green). PRR immunoreactivity is predominantly co-localizedwith
NeuN in SFO, PVN, NTS, RVLM, and AP. Abbreviations: SFO, subfornical organ; PVN, paraventricular nucleus of the hypothalamus; NTS, nucleus of the tractus solitaries; RVLM, rostral
ventrolateral medulla; AP, area posterma; SON, supraoptic nucleus; OVLT, organum vasculosum of the lamina terminalis; CVLM, caudal ventrolateral medulla; NA, nucleus accumbens;
IML, intermediolateral nucleus; PRR, (pro)renin receptor; GFAP, glial ﬁbrillary acidic protein; NeuN, neuronal nuclei.
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diates both Ang II formation and Ang II-independent intracellular
signaling—plays a signiﬁcant role in the development of hypertension
and cardiovascular end-organ damage through prorenin (Ichihara
et al., 2008a) suggests that the PRR might be a promising new target
for the treatment of hypertension. The development and experimental
applications of PRR antagonists are summarized below.
3.1. Handle region peptides
The ﬁrst PRR blocker was a 10-amino-acid decoy peptide with a se-
quence corresponding to the handle region of the prosegment of
prorenin. Both the 10-amino-acid decoy peptide and the entire handle
region peptide (HRP) bind the PRR, but the latter has a lower binding af-
ﬁnity (Nurun et al., 2007). HRP, initially developed by Ichihara and co-
workers (Suzuki et al., 2003; Ichihara et al., 2004), inhibits the
conformational change and non-proteolytic activation of prorenin that
occurs upon binding to the PRR (Morales et al., 2012). HRP has been
shown to attenuate the development of diabetic nephropathy in
streptozotocin-induced diabetic rats and decrease the levels of Ang I
and Ang II, but it has no effect on other components of the RAS (Ichihara
et al., 2004). HRP was also shown to exert a renal-protective effect in
PRR transgenic rats. Over-expression of the human PRR induces slowly
progressing, Ang II-independent glomerulosclerosis in aged rats, an ef-
fect that is signiﬁcantly decreased by chronic infusion of HRP
(Kaneshiro et al., 2007). Overall, these data indicate that HRP has a
greater beneﬁcial effect than ACE-inhibitors in terms of alleviating pro-
teinuria and glomerulosclerosis in experimental animal models of dia-
betes and essential hypertension (Ichihara et al., 2008b). However,
ﬁndings from other independent laboratories have cast doubt on the ef-
ﬁcacy of HRP. In a human renin and AGT double-transgenic rat model,
HRP failed to reduce BP, attenuate albuminuria, or reduce cystatin C
and neutrophil gelatinase-associated lipocalin levels (Feldt et al.,2008). Similarly, HRP does not show a protective effect in the clipped
kidney, Goldblatt hypertensive ratmodel (Krebs et al., 2008).Moreover,
in diabetic TGR(mREN2)27 rats, a well-established nephropathy model
characterized by high prorenin levels, HRPwas shown to counteract the
beneﬁcial effects of aliskiren in the kidney, induce hyperkalemia, and in-
crease plasma plasminogen activator-inhibitor 1, renal COX-2, and car-
diac collagen content (te Riet et al., 2014). A recent study showed that
HRP may actually have an agonistic effect upon binding to the PRR, in-
creasing phosphorylation of ERK1/2 in the retina (Wilkinson-Berka
et al., 2010a). These ﬁndings suggest that HRP may not be stable and
has pleiotropic regulatory effects on PPR activity.
3.2. PRO20
Our laboratory recently developed a PRR peptide antagonist, termed
PRO20 (Li et al., 2015), which is derived from the ﬁrst 20 amino acids of
the prorenin prosegment. The design of PRO20 was based on previous
reports that the physical structure of prorenin presents multiple possi-
ble binding sites for the PRR (Morales et al., 2012). PRO20 contains
most of the previously reported PRR binding sites in the prosegment
of prorenin. In addition, the N-terminus of PRO20 is in close proximity
to a previously identiﬁed PRR-binding domain in both renin and
prorenin (S149PQGVLKEDVF158P), revealed by the three-dimensional
crystal structure of prorenin (Morales et al., 2012). We propose that
PRO20 mimics part of the three-dimensional conformation of the PRR-
binding region of prorenin and acts as a competitive antagonist
(Fig. 4). This conclusion is supported by results of our ﬂuorescent
receptor-binding assays, which showed that FITC-labeled PRO20 bind-
ing to mouse or human PRR is completely blocked by co-incubation
with unlabeled mouse prorenin (Li et al., 2015). PRO20 dose-
dependently binds to mouse and human brain tissue with dissociation
constants (Kd) of about 4.2 and 1.8 nmol/L, respectively. An in vitro
functional study has shown that PRO20 inhibits prorenin (4 nmol/L)-
Fig. 2. Proposed pathways for extra- and intracellular formation of Ang II in neurons. In
presympathetic neurons, prorenin (PR) binds intracellular PRRs, stimulating the
intracellular formation of Ang II, which is subsequently secreted into the extracellular
space. Alternatively, extracellular prorenin binds to PRRs on the neuronal membrane
and metabolizes extracellular AGT secreted by astrocytes or neurons to generate Ang I.
ACE, located on the external surface of cell membranes or in the interstitial ﬂuid,
converts Ang I to Ang II. Intracellular Ang II can be transported to axon terminals to act
as a neurotransmitter. Extracellular Ang II binds to AT1R to modulate neuronal activity
and neurotransmitter release at the synapse. Abbreviations: PR, prorenin; PRR,
(pro)renin receptor; AGT, angiotensinogen; Ang II, angiotensin II; ACE, angiotensin
converting enzyme; AT1R, angiotensin II type 1 receptor; PVN, paraventricular nucleus
of the hypothalamus; RVLM, rostral ventrolateral medulla nucleus. (Modiﬁed from Li W
et al., Hypertension, 2015, 65:352–361.)
Fig. 3.Antihypertensive drugs targeting the RAS. Schematic illustration of clinically approved an
(red square): HRP and PRO20 have been tested in vitro or in animals. Abbreviations: AGT, angiot
AT1R, angiotensin II type 1 receptor; BP, blood pressure; HRP, handle region peptide.
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concentration (IC50) of 81 nmol/L (Li et al., 2015). More importantly,
acute ICV infusion of PRO20 was shown to attenuate prorenin-induced
hypertension and reduce BP in DOCA-salt-induced and genetic hyper-
tensive mice, whereas chronic ICV infusion of PRO20 attenuated the de-
velopment of DOCA-salt-induced hypertension and decreased brain
Ang II formation (Li et al., 2015). Similar effects were also observed in
anAng II-induced rat hypertensionmodel (Wang et al., 2015). Recently,
PRO20 was shown to block prorenin–PRR-induced ENaC (epithelial so-
dium channel) activation, which is triggered by a reactive oxygen spe-
cies (ROS) signaling pathway (Lu et al., 2015). Unique features of
PRO20 compared with HRP revealed by our studies include (1) the
prominent ability of PRO20 to reduce BP and Ang II formation in hyper-
tensive mice; (2) direct competition of PRO20with prorenin to prevent
binding to the PRR; and (3) the ability of PRO20 to prevent prorenin-
induced ERK1/2 phosphorylation in mouse Neuro-2A cells.
3.3. Selectively blocking prorenin/(pro)renin
receptor activation: a new therapeutic strategy for
treatment of hypertension and related cardiovascular complications
In addition to the role of the PRR in mediating Ang II formation and
activation of Ang II-independent signaling by prorenin, the PRR
also plays important roles in cellular homoeostasis through vacuolar
H+-ATPase or canonical and non-canonical Wnt signaling pathways
(Danser, 2009; Ichihara, 2012; Daryadel et al., 2016). The latter has
been shown to be critical for embryonic development, as evidenced by
the embryonic lethality of PRR gene deletion in mouse and zebraﬁsh
models (Danser, 2015). Despite the discovery of the PRR as a novel
tissue Ang II-formation pathway, especially in the CNS (Li et al., 2015),
and the establishment of its importance in tissue ﬁbrosis, inﬂammation
and end-organ damage (Balakumar & Jagadeesh, 2010;
Wilkinson-Berka et al., 2010b), the involvement of the PRR in embryon-
ic development and autophagy has dampened enthusiasm on the part
of the scientiﬁc community and pharmaceutical companies for explor-
ing the PRR as a pharmaceutical target. This lack of enthusiasm stems
from an overly generalized understanding of the complex PRR signaling
pathways. Fig. 4 provides a summary of currently known PRR signaling
pathways. It is clear that the function of the PRR in mediating Wnt sig-
naling is independent of prorenin or renin (Sihn et al., 2010). The role
of the PRR in facilitating vacuolar H+-ATPase activity in autophagy
also does not require prorenin or renin (Cruciat et al., 2010; Daryadel
et al., 2016). Importantly, however, PRR-mediated activation of
MAPKs, including p38, ERK1/2 and JNK signaling pathways, and their
downstream activation of plasminogen activator inhibitor-1 (PAI-1),
TGF-β, and cyclooxygenase 2 (COX2) transcriptional regulation requires
prorenin binding to the PRR (Li et al., 2012b; Danser, 2015; Feng, 2015).
PLZF is a repressive auto-regulatory signaling molecule that is alsotihypertensive agents that inhibit the RAS. Potential newRAS antagonists targeting the PRR
ensinogen; Ang I, angiotensin I; Ang II, angiotensin II; ACE, angiotensin converting enzyme;
Fig. 4. Proposed mechanism for PRO20 blockade of prorenin/PRR activation as a therapeutic strategy. The PRR mediates prorenin (ligand)-dependent signaling by promoting Ang II
formation or Ang II-independent downstream signals. Activation of these prorenin-dependent signaling pathways is responsible for cell proliferation, hypertension, and diabetic end-
organ damage. The PRR also plays important roles in Wnt signaling pathways and autophagy that do not require prorenin. The latter signaling pathways are important for cell survival,
embryonic development, and urine acidiﬁcation. According, we propose that blocking the binding of prorenin to the PRR will prevent prorenin/PRR activation and Ang II formation,
thereby preventing activation of downstream signaling. In addition, blocking activation of prorenin/PRR will not affect the prorenin-independent roles of the PRR in cell survival,
embryonic development, or urine acidiﬁcation. Abbreviations: AGT, angiotensinogen; Ang I, angiotensin I; Ang II, angiotensin II; ACE, angiotensin-converting enzyme; AT1R,
angiotensin II type 1 receptor; PLZF, promyelocytic zinc ﬁnger; MAPKs, mitogen-activated protein kinases; ERK1/2, extracellular signal-regulated kinases 1 and 2; PAI-1, plasminogen
activator inhibitor-1; COX2, cyclooxygenase 2; NOX4, NADPH oxidase 4; LPR6, low-density lipoprotein receptor-related protein 6.
131Q. Xu et al. / Pharmacology & Therapeutics 164 (2016) 126–134induced by the binding of prorenin to the PRR (Schefe et al., 2008). The
pathophysiological effects of the PRR are mostly manifested upon over-
activation of the PRR by prorenin. Accordingly,we propose that blocking
prorenin binding to the PRR (Fig. 4) will prevent activation of speciﬁc
signaling pathways, such as MAPK cascades and their downstream sig-
naling pathways, without affecting the physiological function of PRR in
vacuolar H+-ATPase and Wnt signaling pathways. This conclusion is
supported by previous studies showing that HRP and PRO20 do not pro-
duce overt adverse effects in multiple experimental animal models
(Ichihara et al., 2006; Muller et al., 2008; Li et al., 2015; Wang et al.,
2015). In contrast, deletion of the PRR gene, globally or in speciﬁc tis-
sues, will certainly result in embryonic lethality because of the essential
role of the PRR in H+-ATPase and Wnt pathways (Danser, 2015).
4. Challenges and future directions
A total of 81 antihypertensive drugs have been approved for
hypertension therapy, most of which are ACE-inhibitors, AT1R blockers,
adrenergic receptor blockers (α/β blocker), or calcium channel blockers
(Fig. 5A). Despite the vast array of available drugs, approximately 20–
30% of patients are considered to have resistant hypertension, deﬁned
as BP that is not controlled using three or more types of antihyperten-
sive agents (Calhoun et al., 2008). This creates a need for the develop-
ment of new categories of antihypertensive drugs. The developmentof antihypertensive drugs is still a very active ﬁeld. However, drugs de-
veloped based on novel targets are rare; most ongoing development ef-
forts are focused on existing targets, alone or in combination (Fig. 5B).
The discovery and elucidation of the PRR as a key component of central
BP regulation paves the way for the development of potential new anti-
hypertensive drugs. The success of aliskiren suggests that drugs that act
upstream of the RAS have advantages over traditional antihypertensive
drugs, such as better pharmacokinetics, greater potency (allowing
lower drug doses), and better efﬁcacy with fewer side effects
(Morganti & Lonati, 2011). These advantages make developing new
PRR inhibitors that act upstream of the RAS an attractive proposition.
The development of PRR antagonists such as HRP and PRO20 has
provided pharmacological tools for studying the physiological and
pathophysiological signiﬁcance of the PRR beyond genetic knockdown
models, and suggests the potential of PRR antagonism as a novel ap-
proach for treating hypertension and other cardiovascular diseases.
However, current antagonists of the PRR are all peptide-derived, and
many challenges that hamper their development into viable drugs re-
main. For example, the higher molecular weight of peptides limits
their ability to traverse the BBB, and the relative instability of peptides
in serum makes it difﬁcult to achieve a good pharmacokinetic proﬁle.
Strategies for deliveringdrugs across the BBBhave been explored exten-
sively. One such example is the use of transmembrane peptides, such as
the HIV tat sequence (Wadia & Dowdy, 2005), that directly penetrate
Fig. 5. A global view of antihypertensive drug development. (A) Approved anti-hypertensive drugs with a single ingredient or multiple ingredients. (B) Antihypertensive drugs in
development. Abbreviations: AR, adrenergic receptor; CC, calcium channel; HMGR, HMG CoA reductase; CM, calcium metabolism; MLR, mineralcorticoid receptor; NCC, Na/Cl
transporter; NKCC2, Na–K–Cl cotransporter 2; NPR, natriuretic peptide receptor; nAChR, nicotinic acetylcholine receptor; OR, opioid receptor; PDE5, phosphodiesterase 5; VIPR,
vasoactive intestinal peptide receptor.
132 Q. Xu et al. / Pharmacology & Therapeutics 164 (2016) 126–134the cell membrane. Another strategy is to exploit receptor-mediated
transcytosis, for example by employing a chimeric engineered antibody
against the transferrin receptor, a fusion protein containing transferrin,
and cholera toxin B (Jain & Jain, 2015). Despite their theoretical promise,
the efﬁciency of such engineered chimeric molecules in traversing the
BBB remains inadequate for therapeutic purposes. A breakthrough in
BBB-traversing brain-delivery technology is clearly needed.
In summary, the PRR is an emerging, key component of the RAS that
mediates both Ang II formation and Ang II-independent signaling.
Prorenin, acting via the PRR, plays pivotal roles in regulating BP and car-
diovascular end-organ damage. Although many challenges for the devel-
opment of PRR antagonists remain, accumulating data indicate that the
PRR is an important target for hypertension treatment and suggest that
PRR antagonistsmay represent a new category of antihypertensive drugs.
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